CD274 and neoplasm: Given their different ways of action and complementary functions in immune system modulation, anti-Siglec 15 antibodies show promise as an adjuvant treatment to anti-PD-L1, especially in non-inflammatory (“cold”) tumors or later in the tumor’s development, when the PD-L1 pathway may not be as prominent.